31 articles - From Friday Nov 18 2022 to Friday Nov 25 2022
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
Taxonomy of fibroblasts and progenitors in the synovial joint at single-cell resolution. Our findings blueprint a cell atlas of mouse synovial fibroblasts and progenitors in healthy and injured knees, and provide novel insights into the cellular and molecular principles governing the organisation and maintenance of adult synovial joints. |
| Arthritis Care Res (Hoboken) |
Development and Validation of an Emergency Department Electronic Medical Record Gout Flare Alert. Our multi-component gout flare alert had reasonable sensitivity and specificity, albeit a modest positive predictive value. An electronic gout flare alert may help enable the conduct of gout research in the ED setting. |
| Arthritis Res Ther |
Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study. In BS, organ damage accrues over time, also in long-standing disease, resulting in an impairment of the perceived physical and mental health. Adequate immunosuppressive treatment, preventing disease flares and minimizing exposure to GCs have a crucial role in lowering the risk of damage accrual. |
Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative. LORA and YORA patients had similar prognosis in terms of time to remission. At remission, LORA patients were more likely to be on a single csDMARD without a biologic or JAK inhibitor. |
The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis. We describe a novel approach to study the biological activity of serum LPS and their impact in diseases. The results suggest that LPS contribute to the inflammatory burden and disease activity on patients with RA and that serum-induced TLR4 activation assays can serve as an independent prognostic factor. A graphical summary of the conclusions of the study. |
| Arthritis Rheumatol |
Aberrant naive CD4+ T cell differentiation in systemic juvenile idiopathic arthritis is committed to B cell help. In sJIA pathogenesis skewing of sJIA naïve Th cell differentiation towards a Tf/ph phenotype may represent an echo of autoimmunity, which may indicate mechanisms driving the progression towards chronic destructive arthritis. |
Altered Risk of Incident Gout According to Changes in Metabolic Syndrome Status: A Nationwide Population-Based Cohort Study of 1.29 Million Young Men. Changes in MetS status were associated with altered risk of incident gout. These results suggest that MetS is a modifiable risk factor for gout. |
Early increase of circulating transitional B cells and autoantibodies to joint-related proteins in patients with metastatic melanoma developing checkpoint inhibitor-induced inflammatory arthritis. Development of ICI-IA is accompanied by an increase in transitional B cells and by production of autoantibodies to joint-related proteins. Monitoring of B cell-driven abnormalities upon ICI treatment may help earlier recognition of ICI-IA. |
Gene expression and autoantibody analysis reveals distinct ancestry-specific profiles associated with response to rituximab in refractory systemic lupus erythematosus. Ancestry appears central to the immunological and clinical heterogeneity in SLE. These results suggest that ancestry, disease activity and transcriptional signatures could each assist predict the effectiveness of B-cell depletion. |
Peripheral Blood DNA Methylation-Based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biologic Specimens and Data From the Osteoarthritis Initiative and Johnston County Osteoarthritis Project. Our data suggest that pain and structural progression share similar early systemic immune epigenotypes. Further studies should focus on evaluating the pathophysiologic consequences of differential DNA methylation and peripheral blood cell epigenotypes in individuals with knee OA. |
The T cell receptor repertoire and antigen specificities in small joints of early rheumatoid arthritis - diversity and clonality. Minimally invasive biopsies of the RA synovium allow for single cell TCR-sequencing and phenotyping. Clonally expanded viral-reactive T cells account for part of the diverse CD4+ T cell repertoire. TRBV20-1 bias in ACPA-positive patients suggests recognition of common antigens. |
| Rheumatology (Oxford) |
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab. About one quarter of patients with RA experienced DP, which responded well to sarilumab. These data support the concept that other mechanisms (potentially mediated via interleukin 6) in addition to inflammation may contribute to DP in RA. |
HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients. HOXA5 expression is reduced during the progression of RA and could be a novel therapeutic strategy for modulating the hyperplasia of the synovium, through the regulation of class 3 semaphorins expression. |
Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis. Our study highlights the usefulness of machine learning in unveiling subgroups of inadequate responders to MTX to guide new therapeutic strategies. Further work is needed to validate this approach. |
Methotrexate, leflunomide, and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease. None of the three treatments increased the risk of RA-associated ILD progression, except for leflunomide, which increased the risk of ILD progression in patients with severe ILD. The appropriate use of conventional synthetic disease-modifying antirheumatic drugs considering RA disease activity and ILD severity would be important for the management of RA-associated ILD. |
Microcirculation dynamics in systemic vasculitis: evidence of impaired microvascular response regardless of cardiovascular risk factors. For the first time we have showed that patients with SVs exhibit impaired microvascular function and blunted reactivity after occlusion as this was demonstrated by LSCI technique. Therefore, skin microcirculation may be a useful, non-invasive method in patients with SVs for the early detection of microvascular dysfunction which is closely related to the high CV risk that these patients bear. |
Rheumatoid arthritis macrophages are primed for inflammation and display bioenergetic and functional alterations. This study demonstrates a unique inflammatory and metabolic phenotype of RA monocyte-derived macrophages and identifies a key role for NAMPT and STAT3 signalling in regulating this phenotype. |
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study. While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE. |
Systemic lupus erythematosus phenotypes formed from machine learning with a specific focus on cognitive impairment. This study demonstrates the complexity of cognitive impairment (CI) in SLE and that individual, multi-factorial phenotypes exist. Those with greater disease burden, from SLE specific factors or other factors associated with chronic conditions, report poorer cognitive functioning and perform worse on objective cognitive measures. By exploring different ways of phenotyping SLE we may better define CI in SLE. Ultimately, this will aid our understanding of personalised CI trajectories and identification of appropriate treatments. |
Thrombocytopenia in antiphospholipid syndrome: a free radical perspective. Although antiphospholipid antibodies may induce platelet activation in vitro, additional stimuli may contribute to their activation in vivo, amongst which reactive oxygen and nitrogen species and lipid peroxidation products, elevated in patients with the antiphospholipid syndrome: an excess of the same stimuli may induce megakaryocyte and platelet apoptosis that leads to decreased platelet production and increased destruction, exposure resulting ultimately in thrombocytopaenia. Herein we provide a novel plausible framework involving free radicals that could add to the understanding of the thrombocytopenia/thrombosis paradox in the antiphospholipid syndrome. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Ann Rheum Dis |
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. In clinical trials, most patients have shown to be able to stop GCs within 12-24 months. Well-known safety risks of GC use have been confirmed, but with heterogeneity between studies. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Rheumatology (Oxford) |
Letters to the editors and authors’ replies